Ratings Adocia

Equities

ADOC

FR0011184241

Real-time Euronext Paris Other stock markets 10:07:28 2024-05-03 am EDT			5-day change	1st Jan Change
8.59 ^EUR	+2.14%		-0.35%	-25.56%

Apr. 24	Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 22	Adocia: announces fund-raising	CF

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Its low valuation, with P/E ratio at 4.1 and 2.26 for the ongoing fiscal year and 2024 respectively, makes the stock pretty attractive with regard to earnings multiples.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the past twelve months, EPS forecast has been revised upwards.

Weaknesses

The company's enterprise value to sales, at 6.6 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ADOCIA	-25.56%	129M	-
VERTEX PHARMACEUTICALS INCORPORATED	-1.14%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+7.54%	101B	B+
ARGENX SE	+4.72%	23.07B	B
BIONTECH SE	-12.66%	22.23B	B+
GENMAB A/S	-4.59%	18.05B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.18B	A-
BEIGENE, LTD.	-10.29%	16.94B	B
NEUROCRINE BIOSCIENCES, INC.	+7.14%	14.07B	C+
SAREPTA THERAPEUTICS, INC.	+37.88%	12.35B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes